Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
15
Added to
16
Trimmed
61
Exited
9
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $26.54B across 127 positions in their Q4 2020 SEC 13F filing (period ending 2020-12-31). The top 10 positions account for 84.2% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | $8.28B | 31.19% | - |
| 2 | ONCBeiGene, Ltd. | $3.02B | 11.36% | -12.3% |
| 3 | INCYIncyte Corporation | $2.78B | 10.49% | +0.0% |
| 4 | ACADACADIA Pharmaceuticals Inc. | $2.24B | 8.44% | - |
| 5 | KODKodiak Sciences Inc. | $2.04B | 7.68% | +12.4% |
| 6 | ALXNAlexion Pharmaceuticals, Inc. | $1.37B | 5.16% | - |
| 7 | PRLDPrelude Therapeutics Incorporated | $723.99M | 2.73% | - |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $665.50M | 2.51% | - |
| 9 | NVTA1EURInvitae Corporation | $654.29M | 2.46% | +32.0% |
| 10 | ASNDUSDAscendis Pharma A/S | $590.45M | 2.22% | - |
| Stock | Value | Shares |
|---|---|---|
| ABCLAbCellera Biologics Inc. | $420.51M | 10,450,180 |
| RAREUltragenyx Pharmaceutical Inc. | $61.52M | 444,444 |
| ALGSAligos Therapeutics, Inc. | $44.52M | 1,610,000 |
| OPTEYOpthea Limited | $37.11M | 3,308,705 |
| BCABGBPBioAtla, Inc. | $28.06M | 825,000 |
| VSTMVerastem, Inc. | $21.61M | 10,144,039 |
| MREOMereo BioPharma Group plc | $21.59M | 6,030,293 |
| 290AChinook Therapeutics, Inc. | $11.87M | 748,693 |
| FPRXFive Prime Therapeutics, Inc. | $11.36M | 668,000 |
| SPRYSilverback Therapeutics, Inc. | $11.03M | 238,095 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.